The Risk of Rapid Prostate Specific Antigen Increase in Men With Baseline Prostate Specific Antigen 2.0 ng/ml or Less

Prorok, 2000, Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 273S, 10.1016/S0197-2456(00)00098-2 Schroder, 1999, The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam, Eur Urol, 35, 539, 10.1159/000019894 Standaert, 1997, The European Randomized Study of Screening for Prostate Cancer: an update, Cancer, 80, 1830, 10.1002/(SICI)1097-0142(19971101)80:9<1830::AID-CNCR22>3.0.CO;2-5 Ito, 2001, Long term follow-up of mass screening for prostate carcinoma in men with initial prostate-specific antigen levels of 4.0 ng/ml or less, Cancer, 91, 744, 10.1002/1097-0142(20010215)91:4<744::AID-CNCR1060>3.0.CO;2-C Crawford, 2002, PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial, J Urol, 167, 99 Ito, 2003, Natural history of PSA increase with and without prostate cancer, Urology, 62, 64, 10.1016/S0090-4295(03)00135-3 Pearson, 1994, Natural history of changes in prostate specific antigen in early stage prostate cancer, J Urol, 152, 1743, 10.1016/S0022-5347(17)32375-3 Smith, 1996, Longitudinal screening for prostate cancer with prostate-specific antigen, JAMA, 276, 1309, 10.1001/jama.276.16.1309 de Koning, 2002, Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial, Int J Cancer, 97, 237, 10.1002/ijc.1588 Ito, 1999, The present status, problems, and future of mass screening for prostate cancer in Gunma Prefecture. The report of mass screening for prostate cancer study meeting in 1998, Kitakanto Med J, 49, 81, 10.2974/kmj.49.81